On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera)1.

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as ...

Pfizer and Novo Nordisk have both offered to sweeten their bids for the US obesity biotech Metsera, in the latest development ...

Pfizer et Novo Nordisk se livrent une guerre de milliards pour se positionner sur le marché florissant des médicaments ...

Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other ...

Gold Spot US Dollar, Pfizer Inc, US Dollar Index Futures, S&P 500 Futures. Read 's Market Analysis on Investing.com ...

Pfizer has increased its annual profit forecast and reported higher-than-expected profits for the third quarter amid a legal ...

[NEW YORK] Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow ...

The UK mandates housing for birds to curb bird flu. Philips surpasses profit expectations due to AI tools and tariff ...

The first lawsuit, filed on Friday, claims Novo's bid breaches Pfizer's merger agreement and seeks to bypass antitrust review ...

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...